|
Q3 2024
|
10 |
97,295 |
EWTX, ARVN, CRNX, RLYB
|
13F-HR
|
11/13/2024 |
000095012324011274 |
|
Q2 2024
|
10 |
82,237 |
ARVN, EWTX, CRNX, RLYB
|
13F-HR
|
8/13/2024 |
000095012324008255 |
|
Q1 2024
|
11 |
114,256 |
ARVN, EWTX, DCPH, CRNX
|
13F-HR
|
5/14/2024 |
000095012324005071 |
|
Q4 2023
|
12 |
124,150 |
ARVN, HARP, EWTX, DCPH
|
13F-HR
|
2/13/2024 |
000095012324002003 |
|
Q3 2023
|
12 |
77,875 |
ARVN, DCPH, RLYB, EWTX
|
13F-HR
|
11/13/2023 |
000095012323010254 |
|
Q2 2023
|
14 |
116,438 |
ARVN, RLYB, DICE, DCPH
|
13F-HR
|
8/10/2023 |
000095012323007238 |
|
Q1 2023
|
17 |
121,016 |
ARVN, RLYB, DCPH, DICE
|
13F-HR
|
5/10/2023 |
000095012323004364 |
|
Q4 2022
|
17 |
138,130 |
ARVN, RLYB, DCPH, EWTX
|
13F-HR
|
2/6/2023 |
000095012323000807 |
|
Q3 2022
|
19 |
168,537 |
ARVN, RLYB, DCPH, EWTX
|
13F-HR
|
11/10/2022 |
000095012322011473 |
|
Q2 2022
|
21 |
154,364 |
ARVN, RLYB, DCPH, EWTX
|
13F-HR
|
8/9/2022 |
000095012322008147 |
|
Q1 2022
|
21 |
202,904 |
ARVN, RLYB, HARP, EWTX
|
13F-HR
|
5/6/2022 |
000095012322004719 |
|
Q4 2021
|
22 |
276,016 |
ARVN, HARP, EWTX, RLYB
|
13F-HR
|
2/11/2022 |
000095012322002158 |
|
Q3 2021
|
22 |
346,698 |
ARVN, DCPH, RLYB, EWTX
|
13F-HR
|
11/12/2021 |
000095012321015005 |
|
Q2 2021
|
19 |
389,597 |
ARVN, CRNX, EWTX, DCPH
|
13F-HR
|
8/12/2021 |
000095012321010563 |
|
Q1 2021
|
18 |
429,664 |
ARVN, HARP, DCPH, EWTX
|
RESTATEMENT
|
8/12/2021 |
000095012321010559 |
|
Q4 2020
|
17 |
432,816 |
ARVN, DCPH, PASG, HARP
|
13F-HR
|
2/10/2021 |
000095012321001531 |
|
Q3 2020
|
18 |
248,188 |
DCPH, ARVN, HARP, PASG
|
13F-HR
|
11/12/2020 |
000095012320011526 |
|
Q2 2020
|
20 |
348,503 |
ARVN, DCPH, PASG, HARP
|
13F-HR
|
8/13/2020 |
000095012320008667 |
|
Q1 2020
|
20 |
334,291 |
ARVN, DCPH, PASG, HARP
|
13F-HR
|
5/14/2020 |
000095012320004944 |
|
Q4 2019
|
19 |
460,293 |
DCPH, ARVN, SIERRA ONCOLOGY INC, PRNB
|
13F-HR
|
2/13/2020 |
000095012320001663 |
|
Q3 2019
|
19 |
330,614 |
DCPH, PRNB, ARVN, HARP
|
13F-HR
|
11/14/2019 |
000095012319011396 |
|
Q2 2019
|
21 |
373,081 |
DCPH, PRNB, ARVN, HARP
|
13F-HR
|
8/13/2019 |
000095012319007826 |
|
Q1 2019
|
20 |
364,942 |
DCPH, PRNB, ARVN, HARP
|
RESTATEMENT
|
6/4/2019 |
000095012319005820 |
|
Q4 2018
|
20 |
364,301 |
DCPH, PRNB, APTX, STIM
|
13F-HR
|
2/13/2019 |
000095012319001688 |
|
Q3 2018
|
20 |
549,556 |
DCPH, APTX, PRNB, STIM
|
13F-HR
|
11/13/2018 |
000095012318011341 |
|
Q2 2018
|
15 |
414,327 |
DCPH, APTX, STIM, CRSP
|
13F-HR
|
8/14/2018 |
000095012318008914 |
|
Q1 2018
|
14 |
185,189 |
DCPH, CRSP, WVE, OBSV
|
13F-HR
|
5/15/2018 |
000095012318005795 |
|
Q4 2017
|
16 |
213,809 |
DCPH, PDSB, IRTC, WVE
|
13F-HR
|
2/14/2018 |
000095012318002471 |
|
Q3 2017
|
16 |
215,484 |
DCPH, IRTC, PDSB, OXFORD IMMUNOTEC GLOBAL PLC
|
13F-HR
|
11/14/2017 |
000095012317010937 |
|
Q2 2017
|
15 |
142,363 |
IRTC, ARAV, PDSB, OXFORD IMMUNOTEC GLOBAL PLC
|
13F-HR
|
8/14/2017 |
000101297517000625 |
|
Q1 2017
|
16 |
195,197 |
IRTC, ARAV, PDSB, WVE
|
13F-HR
|
5/15/2017 |
000101297517000408 |
|
Q4 2016
|
15 |
139,613 |
ARAV, PDSB, OXFORD IMMUNOTEC GLOBAL PLC, WVE
|
13F-HR
|
2/14/2017 |
000101297517000134 |
|
Q3 2016
|
14 |
138,901 |
WVE, ARAV, PDSB, OXFORD IMMUNOTEC GLOBAL PLC
|
13F-HR
|
11/14/2016 |
000163161416000007 |
|
Q2 2016
|
14 |
116,235 |
PDSB, ARAV, WVE, OXFORD IMMUNOTEC GLOBAL PLC
|
13F-HR
|
8/15/2016 |
000163161416000006 |
|
Q1 2016
|
13 |
110,496 |
PDSB, ARAV, DMTX, OXFORD IMMUNOTEC GLOBAL PLC
|
13F-HR
|
5/16/2016 |
000101297516001257 |
|
Q4 2015
|
10 |
149,381 |
PDSB, ARAV, DMTX, ALDR
|
13F-HR
|
2/16/2016 |
000163161416000005 |
|
Q3 2015
|
13 |
115,286 |
ARAV, ALDR, OXFORD IMMUNOTEC GLOBAL PLC, DVAX
|
13F-HR
|
11/16/2015 |
000163161415000004 |
|
Q2 2015
|
14 |
150,879 |
ALDR, ARAV, OXFORD IMMUNOTEC GLOBAL PLC, CMRX
|
13F-HR
|
8/14/2015 |
000163161415000003 |
|
Q1 2015
|
13 |
147,301 |
ARAV, RELYPSA INC, OXFORD IMMUNOTEC GLOBAL PLC, ALDR
|
13F-HR
|
5/15/2015 |
000101297515000410 |
|
Q4 2014
|
13 |
205,507 |
ARAV, RELYPSA INC, CMRX, OXFORD IMMUNOTEC GLOBAL PLC
|
13F-HR
|
2/17/2015 |
000163161415000001 |